KR

About

In 2011, Dr. Yi Rang Kim met Dr. Jin Woo Choi in Massachusetts General Hospital. Dr. Kim was a
Ph.D. candidate and Mr. Choi was a postdoc. They met as a physician and biologist discussing
basic research and the deficiencies in research and clinical research. They promised to work
together someday because they could fill each other's gaps if they worked together later. After
receiving a doctorate in KAIST, Dr. Kim finished his medical training in oncology. Meanwhile,
Dr. Choi became a professor of pharmacology in Kyunghee University. Dr.Kim felt sorry for the
patients who could not receive treatment due to the high cost of the drugs or their deficiency
and discussed with Mr. Choi how to solve the problem. Then, they founded Oncocross.

CEO Greeting

“Until now, many patients, especially cancer patients,
have suffered from medical enigmas.”

Oncocross has strived for discovering drugs that can satisfy unmet needs in numerous diseases
and medical conditions. While treating cancer patients, a number of patients complained about sar-
copenia and Oncocross has developed the sarcopenia drugs which are one of our pipelines. These
safe sarcopenia drugs also expand ALS survival significantly. In this way, we will continue to find
safe and effective drugs. Oncocross will do its best until all the patients are happy.

CEO:Yi Rang Kim MD, Ph.D.

Advisory Board

  • CEO

    Yi Rang Kim MD, Ph.D.

    Medical Oncologist

    Ph.D. at KAIST
  • Vice President

    Eun Jin JouM.D.

    Bioinformatics specialist

    Computational genomics
    at Harvard
    Pharmacodesign Ex CEO
  • Vice President

    Seung Hyun Park MS

    Drug develop specialist

    Ex Daewoong, Kolon Pharm.
    Domestric L/O
  • Scientific Advisor

    Jin Woo ChoiPh.D

    Big Data specialist

    Associate professor
    College of Pharmacy
    Kyunghee university
  • Advisor

    Wan Seok JooPh.D

    RA specialist

    Ex KFDA officer
    Director at CLIPS
  • AI Director

    Young Heun Lee Ph.D

    Biostatistics

    Ph.D at Chung-ang
    university
  • BI Team Leader

    Woo Gwang SimPh.D

    Bioinformatics

    Ph.D at KAIST
  • AI Team Leader

    Gwang Yeul YunPh.D

    Artificial Intelligence

    Ph.D at Dankook university
  • Associate Researcher

    Myung Hyun KimMS

    Artificial Intelligence

     
  • Researcher

    Jun Hee Jo  

    Bioinformatics

     
  • Research Director

    Sang Yun ParkPh.D

    Ph.D at Kyunghee university
  • Associate Researcher

    Ga Eul YangMs

     

     
  • Associate Researcher

    Seung Jun LeeMs

     

     
  • Associate Researcher

    Hui Jung Na  

     

     
  • Advisor

    Young Soo Moon MBA

    MBA at Yonsei university,
    President_BL&H USA LLC
  • Director

    Ki Baek Park 

     

     

History

2015.07

~ NOW

  • 2020
    01. L/I about new indication of JPI-289 of Jeil Pharma
    01. CDA with Columbia university
  • 2019
    10. Elected as a merit institution/corporation for health
    and medical technology business by the Ministry of
    Health and Welfare
    10. MOU with Huons Co. Ltd.
    09. Has discovered the optimal cancer and its indications
    for specific anti-cancer drugs with ST Pharm and has
    discovered biomarkers
    08. CDA with Novo Nordisk
    08. MOU with CMG Pharm Co., Ltd.
    05. Series A (5 billion) investment completed.
  • 2018
    11. Participated in a project led by Korea Technology and
    Information Promotion Agency for SMEs
    11. Participated in a project led by Korea Institute of
    Startup & Entrepreneurship Development
    10. MOU with Korea Research Institute
    of Chemical Technology
    02. Individual countries patent application
    for liver cirrhosis & NAFLD
    (18 countries including USA, EU, Japan, China)
  • 2017
    08. Business address changed (Gong-deok building)
    04. Participated in a project led by Ministry
    of Health and Welfare
    02. Two patented technologies transferred
  • 2016
    12. Antibody Therapeutics Development Technology
    Licensing Out
    04. Approved as a “venture company”
  • 2015
    11. Seven patented technologies transferred
    09. Establishment of R&D center in Korea
    07. Foundation of Oncocross Co., Ltd

CI

‘Onco’

is a prefix that means tumor.

'Cross'

represents our technology and commitment to develop new drugs using convergent sciences.